Emma Meagher Speaks at FDA: Agency Turns to AI to Speed Up Clinical Trials
The FDA recently announced a revolutionary pilot program to review clinical trial data in real-time. By utilizing cloud-based platforms and AI, regulators can now see safety signals and clinical endpoints as they happen—rather than waiting months for data transfers. At Penn Medicine, we are proud to be at the forefront of this shift. Emma A. Meagher, M.D., senior vice dean for clinical and translational research, joined the FDA's press conference to share why this is such a pivotal moment for the field.